In terms of key secondary outcomes, mean changes from baseline in body weight at week 26 were -1.2 kg, -2.2 kg, and -3.1 kg for semaglutide 3 mg, 7 mg, and 14 mg, respectively
GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity
The RxSpan MD Refund Cliff: What Can Become Non-Refundable, and When Quick Answer: In telehealth programs like RxSpan MD, the most important refund question is timing - what's refundable before a prescription is written versus after
The FDA also found that some companies obscured the compounded nature of their products or failed to adequately disclose the source of the compounded drug